TICKERNERD
Menu
TNXPTNXPHealthcare · Biotechnology

TNXP Stock Forecast: Tonix Pharmaceuticals Holding Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$12
−3.58% on the day

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. hold a median 12-month price target of $34 — +187.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$203.1M
Ticker Nerd rank
27 / 100
Median analyst target
$34
Analysts covering
4
Revenue$13.5M+577.9% y/y
Operating income−$41.9M
Net income−$40.6M
Free cash flow−$42.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.4%
1M
−4.1%
YTD
−24.2%
1Y
−62.1%
From 52W high
−62.1%
From 52W low
+24.5%
$10
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tonix Pharmaceuticals Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
73
Size
68
Quality
64
Growth
42
Volatility
39
Accruals
34
Value
21
Issuance
16
Momentum
6

Revisions (73): Analysts have, on balance, been raising their forecasts.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TNXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26TNXPHigh $65Median $34Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $22Median $34High $65

The green dot is the last close — the median target sits +187.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 June 2026Raymond JamesInitiatesStrong Buy$26
4 May 2026TD CowenInitiatesBuy—
20 Mar 2025Noble Capital MarketsReiteratesOutperform—
22 July 2024Alliance Global PartnersMaintainsBuy—
28 Feb 2024Dawson JamesInitiatesBuy—
1 Aug 2023Alliance Global PartnersMaintainsBuy—
2 June 2023Alliance Global PartnersMaintainsBuy—
12 Jan 2023Alliance Global PartnersReiteratesBuy$6.50
18 Apr 2022Noble Capital MarketsInitiatesOutperform$0.60
31 Aug 2021Alliance Global PartnersMaintainsBuy—
11 Aug 2021Alliance Global PartnersMaintainsBuy—
25 Feb 2021Alliance Global PartnersMaintainsBuy—
18 Nov 2019B. Riley FBRDowngradeNeutral—
18 Nov 2019Cantor FitzgeraldDowngradeHold—
18 Nov 2019Janney CapitalInitiatesBuy—
18 Nov 2019OppenheimerMaintainsOutperform—
18 Nov 2019Roth CapitalUpgradeBuy—
18 Apr 2019Roth CapitalUpgradeBuy—
27 July 2018B. Riley FBRDowngradeNeutral—
27 July 2018Roth CapitalDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TNXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Tonix Pharmaceuticals Holding Corp. returned −62.1% against +17.5% for the S&P 500, dividends included.

TNXP vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26TNXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TNXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Tonix Pharmaceuticals Holding Corp. (TNXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
7.0×

Cheaper than 18% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
577.9%

Higher than 98% of US stocks

Earnings growth (YoY)
577.9%

Higher than 96% of US stocks

Gross margin
94.8%

Higher than 98% of US stocks

Operating margin
−314.1%

Higher than 9% of US stocks

Net margin
49.3%

Higher than 96% of US stocks

Returns & dividend
Return on equity
−81.8%

Higher than 16% of US stocks

Return on assets
−46.8%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tonix Pharmaceuticals Holding Corp. (TNXP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tonix Pharmaceuticals Holding Corp. has a market value of $203.1M and an enterprise value of $28.6M.

  • Revenue in the twelve months to 30 June 2026: $29.1M. The latest quarter grew 577.9% year on year.

  • Net income over the same four quarters: −$159.7M, a −548.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−12.94.

  • Free cash flow in the twelve months to 30 June 2026: −$156.1M.

  • Tonix Pharmaceuticals Holding Corp. spent $7.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 16.8M.

  • Trailing P/E: 0.1×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tonix Pharmaceuticals Holding Corp. employs 142 people — $205K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

TNXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNXPTonix Pharmaceuticals Holding Corp.$203.1M
27
PEPGPepGen Inc.$204.8M
46
NKTXNkarta, Inc.$207.5M
42
KRROKorro Bio, Inc.$199.2M
29
CHRSCoherus Oncology, Inc.$198.8M
52
CUECue Biopharma, Inc.$208.8M
40
DTILPrecision BioSciences, Inc.$197.9M
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tonix Pharmaceuticals Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNXP news & analysis

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

MarketBeat · 12 Sept 2026neutral

At the Cantor Healthcare Conference, Tonix Pharmaceuticals CEO Seth Lederman said the company's near-term focus is the commercial launch of TONMYA, its FDA-approved fibromyalgia treatment, while it continues advancing Lyme disease prevention and transplant rejection programs.

Why it matters — TNXP watchers would care because the company's stated priorities clarify its commercial and developmental roadmap as its Lyme disease prevention trial moves closer.

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

GlobeNewsWire · 8 Sept 2026neutral

Tonix Pharmaceuticals announced the promotion of Thomas Englese, MBA, to Chief Commercial Officer, effective immediately. The appointment was announced by the fully integrated, commercial-stage biopharmaceutical company on September 8, 2026.

Why it matters — TNXP watchers would follow this leadership change as the new Chief Commercial Officer will oversee the company's commercialization efforts.

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Tonix Pharmaceuticals announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor's 2026 Global Healthcare Conference, held September 9-11, 2026, in New York. The announcement was made on September 2, 2026.

Why it matters — The company's participation in a major healthcare conference could increase visibility among investors and industry participants.

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

MarketBeat · 18 Aug 2026positive

Tonix Pharmaceuticals CEO Seth Lederman presented the company's near-term strategy during a Canaccord Genuity conference, highlighting the commercial launch of TONMYA for fibromyalgia along with advancing development programs in Lyme disease prevention and major depressive disorder.

Why it matters — TNXP watchers would care because the update outlines the company's strategic priorities around its commercial product and pipeline direction.

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Tonix Pharmaceuticals Holding Corp. held its second-quarter 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. No other details were provided in this item.

Why it matters — A Tonix watcher would look to the earnings-call transcript for the company's own commentary on its quarterly results and outlook.

FAQ

Frequently asked questions about TNXP stock

What is the TNXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. have a median 12-month price target of $34, with estimates ranging from $22 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNXP stock a buy right now?

Of the 4 analysts covering Tonix Pharmaceuticals Holding Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tonix Pharmaceuticals Holding Corp. 27 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNXP?

As at 12 Sept 2026, Tonix Pharmaceuticals Holding Corp. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (73 of 100).

Will TNXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +187.2% from the last close, and Ticker Nerd's factor model ranks Tonix Pharmaceuticals Holding Corp. 27 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNXP stock forecast for 2030?

No analyst covering Tonix Pharmaceuticals Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $65 over the next 12 months.

How has TNXP stock performed over the past year?

Tonix Pharmaceuticals Holding Corp. returned -62.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases.

What is the latest news on TNXP?

The most recent item we track (MarketBeat, 12 Sept 2026): "Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears". At the Cantor Healthcare Conference, Tonix Pharmaceuticals CEO Seth Lederman said the company's near-term focus is the commercial launch of TONMYA, its FDA-approved fibromyalgia treatment, while it continues advancing Lyme disease prevention and transplant rejection programs.

Company

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases. Tonix Pharmaceuticals Holding Corp. markets approved and late-stage products for conditions with significant unmet medical need, including TONMYA for fibromyalgia and additional medicines used in migraine care. The company’s pipeline includes programs aimed at neurological, infectious, and immune-related diseases, reflecting a broad research and development platform built around small molecules and biologics. Tonix Pharmaceuticals Holding Corp. serves the U.S. healthcare market through a combination of commercial products, clinical development programs, and disease-focused collaborations. Its role in the financial market is defined by its position as a commercial-stage biotechnology business with a diversified therapeutic portfolio and ongoing pipeline activity.

CEO Dr. Seth Lederman M.D. · 142 employees · United States · https://www.tonixpharma.com